Astellas Pharma Inc. (TSE:4503) entered into a definitive agreement to acquire Ogeda SA from Vesalius Biocapital II SA SICAR managed by Vesalius Biocapital Partners S.à r.l., Fund+ NV, Société Régionale d'Investissement de Wallonie S.A., Capricorn Health-Tech Fund NV managed by Capricorn Venture Partners, BNP Paribas Fortis Private Equity and others for €800 million on April 2, 2017. Astellas will make an initial payment of €500 million. Ogeda shareholders will be eligible to receive an additional €300 million with attainment of certain clinical development and regulatory milestones for fezolinetant. The consideration will be financed from cash on hand. Upon completion of the transaction, Ogeda would become a wholly owned subsidiary of Astellas. The closing of the transaction is subject to certain conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of the United States, and is expected to be finalized in the second quarter of 2017. Thomas De Muynck, Christian B. Fulda, Jonn Beeson, Philipp Werner, Chantal Biernaux, Michael Knight, Warren Nachlis, Jeremy Cole, Werner Heyvaert, Jonas van den Bossche, Marilyn Jonckheere, Thibault de Boulle, Astrid De Winne, Katherine Llewellyn, Valérie Oyen, Stefanie Tack, Alexander von Homeyer and John Magruder of Jones Day acted as legal advisors to Astellas Pharma. Thierry Bosly, Muriel Alhadeff, Hadrien Servais, Nathalie Colin, Pontus Lindfelt, Rebecca Farrington, Bertrand Liard, Tom Matthijs, Thomas Glauden, Camille Deveseleer, Franck Lupinacci, Alexandre Hublet, Aurélie Terlinden and Daniel Rosenthal of White & Case LLP acted as legal advisor to Ogeda SA. Astellas Pharma Inc. (TSE:4503) completed the acquisition of Ogeda SA from Vesalius Biocapital II SA SICAR managed by Vesalius Biocapital Partners S.à r.l., Fund+ NV, Société Régionale d'Investissement de Wallonie S.A., Capricorn Health-Tech Fund NV managed by Capricorn Venture Partners, BNP Paribas Fortis Private Equity and others on May 17, 2017.